The Executive Team at Immuron is made up of extraordinarily talented individuals who bring to the company years of experience in their respective fields and have proven expertise in building innovative pipelines. Our team’s experience spans the full spectrum of discovery, clinical, regulatory and commercial with a strong track record in execution. We are focused on capitalizing on the programs we prioritize and to bringing life saving medicines to those patients who suffer from the diseases we target.
Chief Executive Officer
Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This includes valuable experience in mergers and acquisitions, finance, business development, sales and marketing, manufacturing, and research and development.
Mr. Lydeamore was most recently Chief Executive Officer (CEO) of Anatara Lifesciences Limited (ASX:ANR), during which time the company successfully transitioned from a preclinical to a clinical company following development of a gastrointestinal tract delivery technology from which two products have commenced human clinical trials.
Chief Operating Officer
Dr Jerry Kanellos has over twenty years’ experience in the pharmaceutical and biotechnology industry, and has held leadership roles in business development, project management, intellectual property portfolio management, research and development and senior management, and holds a PhD in medicine from the University of Melbourne.
Dr Kanellos has worked as a consultant to the biotechnology industry and has provided development and commercialisation strategies for various bodies including academic institutes, private and publicly listed companies, and government departments. He has also been involved in the establishment and management of several startup biotechnology companies.
During his ten years tenure in research and development at CSL Limited, Dr Kanellos gained considerable experience in the drug development process, formulation development through to pharmaceutical scale up and cGMP manufacture successfully leading the Chemistry Manufacturing and Controls (CMC) programs for the approval, manufacture and launch of several products.
Chief Commercial Officer
Flavio is a successful, commercial leader with over 20 years extensive global management and business development experience. Flavio has extensive consumer healthcare experience holding leadership roles for GlaxoSmithKline (GSK) locally (Australia & NZ), regionally (South East Asia) and Globally where he has been responsible for developing strategic plans and achieving hyper growth targets.
Flavio’s experience extends to sales & marketing leadership roles for Procter & Gamble (P&G) in the UK, Europe and Australia and Deloitte in Australia. MBA qualified from the University of Adelaide, with a proven record of accomplishment in commercial strategy, sales, marketing, brand and product management, communication, finance, digital technology and product innovation.
Director of US Sales
Travis is an accomplished, motivated leader with progressive years of proven success in dramatically increasing revenues and expanding market shares, while building key relationships. Building and leading top performing sales teams that embrace the highest standards of customer relationship management and retention. Excels at interacting with broad populations including senior management, staff, manufacturers, distributors, clinical professionals at physician practices, hospitals, government accounts, such as the VA, National and Regional accounts, clinics and universities. Effectively defines, develops and implements targeted action plans to maximize productivity, efficiency and profitability. Highly versatile; quickly masters new roles, responsibilities, technologies, and environments. Reputation for integrity, problem solving abilities, work ethic, and analytical skills.
Manufacturing Quality Director
Mr Moussakhani MEng. (CP), Grad. Cert. (Eng Mgt), BSc. (Chemistry), Dip. Bus. (FM), is a professional operations and production manager with over 25 years experience in the implementation of project, quality and process improvements in the manufacture of therapeutics. He has effectively managed all aspects of goods manufacturing practice production and worked with companies such as Hospira, Sigma Pharmaceuticals, Ensign Laboratories and Quantum.
Company Secretary & Chief Financial Officer
Phillip Hains is a Chartered Accountant and specialist in the public company environment who has served the needs of a number of public company boards of directors and related committees. He has over two decades of experience in providing accounting, administration, compliance and general management services. Holding a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants, Mr Hains is currently a Non-Executive Director of Savcor Limited (ASX:SAV) and of Non-For-Profit organisation Outward Bound Australia.
Dr Joanne Casey
Research & Development Manager
Dr Joanne Casey has an extensive background in clinical and translational research spanning more than two decades of academic and biotechnology industry environments. Dr Casey has been active in the fields of antibody engineering and she has gained extensive experience in both research management and project management at the interface of discovery and clinical translation.
Dr Casey has a PhD (Medicine) from University College London (UCL) developing recombinant antibodies for targeting colorectal tumours in patients. During her career she has discovered and developed many antibodies resulting in over 30 journal publications including Nature Medicine and Cell and is an inventor on several granted patents and patent applications. Dr Casey has led Australian biotechnology antibody research and development programs and has worked closely with global biotechnology and pharma companies to translate human antibodies into pre-clinical and clinical trials.